|Bid||6.10 x 2200|
|Ask||30.00 x 1300|
|Day's Range||7.05 - 7.45|
|52 Week Range||3.33 - 11.93|
|Beta (3Y Monthly)||2.55|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It is doubtless a positive to see that the Neurotrope, Inc. (NASDAQ:NTRP) share price has gained some 38% in the last...
Neurotrope Inc (NASDAQ: NTRP) announced Monday that it has initiated enrollment for a confirmatory Phase 2 study of bryostatin-1 in Alzheimer’s disease. The typically good news of a drug candidate's progress may not be enough to clear the public's memory of Neurotrope. In early 2017, Neurotrope popped nearly 250 percent after early expectations for bryostatin suggested leadership in Alzheimer’s research.
Alzheimer’s disease affects some 5.7 million Americans, but biotech company Neurotrope is offering patients new hope with a drug it says shows a “reversal” in the disease. Yahoo Finance’s Alexis Christoforous speaks to Neurotrope CEO Dr. Charles Ryan about his company’s findings.